Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.

Abstract

INTRODUCTION:

The VISIONARY study demonstrated statistically significant intraocular pressure (IOP) reductions with the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% (PF tafluprost/timolol FC) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients, sub-optimally controlled with topical prostaglandin analogue (PGA) or beta-blocker monotherapy. Current subanalyses have examined these data according to the baseline monotherapy.

METHODS:

A European, prospective, observational study included adults (aged ≥ 18 years) with OAG or OHT, who were switched to the PF tafluprost/timolol FC from PGA or beta-blocker monotherapy. Treatment outcomes were reported according to prior monotherapy subgroup: beta-blocker, preserved latanoprost, PF-latanoprost, bimatoprost, tafluprost, and travoprost. Endpoints included the mean change from baseline regarding IOP, conjunctival hyperemia, and corneal fluorescein staining (CFS) at Week 4 and Week 12, and at Month 6.

RESULTS:

The subanalysis included 577 patients. All prior monotherapy subgroups demonstrated statistically significant IOP reductions from baseline at Week 4, that were maintained through Month 6 (p < 0.001). Mean (SD) IOP change at Month 6 was 6.6 (4.16), 6.3 (4.39), 5.6 (3.67), 4.9 (2.97), 4.6 (4.39), and 4.7  (3.64) mmHg for prior beta-blocker, preserved latanoprost, PF-latanoprost, tafluprost, bimatoprost, and travoprost subgroups, respectively. The largest IOP change was observed in the preserved latanoprost subgroup for each of the ≥ 20%, ≥ 25%, ≥ 30%, and ≥ 35% IOP reduction categories at Month 6, demonstrating respective reductions of 8.06, 9.20, 10.64, and 11.55 mmHg. CFS was significantly reduced at Month 6 in the prior bimatoprost subgroup (p = 0.0013). Conjunctival hyperemia severity was significantly reduced at each study visit for prior preserved latanoprost users (p < 0.001).

CONCLUSION:

PF tafluprost/timolol FC therapy provided statistically and clinically significant IOP reductions from Week 4 over the total 6-month period, in patients with OAG/OHT, regardless of the type of prior PGA or beta-blocker monotherapy used. Conjunctival hyperemia severity and CFS decreased significantly in prior bimatoprost and preserved latanoprost users, respectively.

CLINICAL STUDY NUMBER:

European Union electronic Register of Post-Authorization Studies (EU PAS) register number: EUPAS22204.

• Authors: Francesco Oddone, James Kirwan, Fernando Lopez-Lopez, Marina Zimina, Claudia Fassari, Gábor Holló, VISIONARY Study Group
• Journal: Advances in therapy (Adv Ther) Vol. 39 Issue 8 Pg. 3501-3521 (08 2022) ISSN: 1865-8652 [Electronic] United States
• PMID: 35524840 (Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
• Copyright: © 2022. The Author(s).

Chemical References

• Antihypertensive Agents
• Drug Combinations
• Prostaglandins A
• Prostaglandins F
• tafluprost
• Latanoprost
• Timolol
• Bimatoprost
• Travoprost

Topics

• Adult
• Antihypertensive Agents (adverse effects)
• Bimatoprost (therapeutic use)
• Drug Combinations
• Glaucoma (drug therapy)
• Glaucoma, Open-Angle (drug therapy)
• Humans
• Hyperemia (chemically induced, drug therapy)
• Intraocular Pressure
• Latanoprost (therapeutic use)
• Ocular Hypertension (chemically induced, drug therapy)
• Prospective Studies
• Prostaglandins A (therapeutic use)
• Prostaglandins F
• Timolol (adverse effects)
• Travoprost (therapeutic use)